UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the "Board") granted a stock-based award to a new employee, Federico Grossi, UNITY's Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
加利福尼亞州南舊金山，2025年1月7日（GLOBE NEWSWIRE）——開發減緩、阻止或逆轉衰老疾病療法的生物技術公司Unity Biotechnology, Inc.（「UNITY」）[納斯達克股票代碼：UBX] 今天宣佈，董事會薪酬委員會（「董事會」）於2025年1月6日向新員工費德里科·格羅西授予股票獎勵，UNITY的首席醫療官，涵蓋購買15萬股UNITY普通股的期權。股票獎勵是根據經修訂的UNITY 2020就業激勵計劃發放的，該計劃於2020年3月獲得董事會批准，旨在根據納斯達克股票市場規則5635（c）（4），向新僱員提供補助金，以此作爲他們開始在UNITY工作的實質性誘因。
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at or follow us on Twitter and LinkedIn.
關於 UNITY
UNITY正在開發一種新的療法，以減緩、阻止或逆轉衰老疾病。UNITY目前的重點是開發藥物，以選擇性地消除或調節衰老細胞，從而爲與年齡相關的眼科和神經系統疾病提供變革性益處。更多信息可在推特和領英上獲得或關注我們。
Media Contact
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com
媒體聯繫人
Inizio Evoke Comms
凱瑟琳史密
katherine.smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
投資者聯繫方式
LifeSCI 顧問有限責任公司
喬伊斯·阿萊爾
jallaire@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
